Integrated BioPharma Q4 FY22 net income $1.5M, down 67% YoY; revenue falls 22%

INTEGRATED BIOPHARMA INC

Q4 revenue $13.3M, down 22.2% from $17.1M; operating income $0.4M vs $1.3M.
Full fiscal year revenue $56.2M, down 11.6% from $63.6M; operating income $2.7M vs $5.8M.
Full year diluted EPS $0.12 vs $0.25; net income $3.8M vs $8.0M.
Co-CEOs cite normalization after pandemic-driven safety stock and demand as reasons for decline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.